Lowest Glucose Variability for Insulin + GLP-1 RA in T2DM

Share this content:
Lowest Glucose Variability for Insulin + GLP-1 RA in T2DM
Lowest Glucose Variability for Insulin + GLP-1 RA in T2DM

TUESDAY, Dec. 20, 2016 (HealthDay News) -- For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study published online Dec. 2 in Diabetes Care.

Harpreet S. Bajaj, M.D., M.P.H., from LMC Diabetes & Endocrinology in Brampton, Canada, and colleagues compared GV using continuous glucose monitoring (CGM) in patients with well-controlled type 2 diabetes using four insulin regimens: basal insulin + oral drugs (BO), BGLP, premixed insulin (PM), and basal-bolus insulin (BB). One hundred sixty patients underwent six-day masked CGM in four equal insulin regimen cohorts.

The researchers found that the primary outcome of the daily glucose standard deviation was significantly lower in the BGLP cohort compared with the BO (P = 0.03), PM (P = 0.01), and BB (P < 0.01) cohorts; these correlations persisted after adjustment for age, body mass index, type 2 diabetes duration, and hemoglobin A1c. The BGLP cohort had the lowest daily hypoglycemia outcomes on CGM.

"These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »